Macupatide

DRUG3 trials

Sponsors

Eli Lilly and Company

Conditions

Diabetes Mellitus, Type 2ObesityOverweight

Phase 1

A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes

Not yet recruitingNCT07765511

Eli Lilly and CompanyObesity, Overweight

Start: 2026-10-01End: 2027-06-01Target: 60Updated: 2026-08-14

Phase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

RecruitingNCT07215559

Eli Lilly and CompanyObesity, Overweight, Diabetes Mellitus, Type 2

Start: 2025-10-16End: 2027-05-01Target: 200Updated: 2026-09-08

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

RecruitingNCT07589608

Eli Lilly and CompanyOverweight, Obesity

Start: 2026-05-15End: 2028-02-01Target: 400Updated: 2026-08-06